This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Raut CP, Morgan JA, Ashley SW. Current issues in gastrointestinal stromal tumors: incidence, molecular biology, and contemporary treatment of localized and advanced disease. Current opinion in gastroenterology. 2007;23:149–58.RautCPMorganJAAshleySWCurrent issues in gastrointestinal stromal tumors: incidence, molecular biology, and contemporary treatment of localized and advanced disease20072314958Search in Google Scholar
Chung JC, Kim HC, Hur SM. Limited resection for duodenal gastrointestinal stromal tumors and their oncologic outcomes. Surg Today. 2016;46:110–6.ChungJCKimHCHurSMLimited resection for duodenal gastrointestinal stromal tumors and their oncologic outcomes2016461106Search in Google Scholar
Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, et al. Efficacy and safetyof imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002;347:472–80.DemetriGDvon MehrenMBlankeCDVan den AbbeeleADEisenbergBRobertsPJHeinrichMCTuvesonDASingerSJanicekMEfficacy and safetyof imatinib mesylate in advanced gastrointestinal stromal tumors200234747280Search in Google Scholar
Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, McArthur G, Judson IR, Heinrich MC, Morgan JA, et al. Efficacy and safety of unitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet. 2006;368:1329–38.DemetriGDvan OosteromATGarrettCRBlacksteinMEShahMHVerweijJMcArthurGJudsonIRHeinrichMCMorganJAEfficacy and safety of unitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial2006368132938Search in Google Scholar
Demetri GD, Reichardt P, Kang YK, Blay JY, Rutkowski P, Gelderblom H, Hohenberger P, Leahy M, von Mehren M, Joensuu H, et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381:295–302.DemetriGDReichardtPKangYKBlayJYRutkowskiPGelderblomHHohenbergerPLeahyMvon MehrenMJoensuuHEfficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial2013381295302Search in Google Scholar
Raut CP, Posner M, Desai J, Morgan JA, George S, Zahrieh D, Fletcher CD, Demetri GD, Bertagnolli MM. Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. J Clin Oncol. 2006;24:2325–31.RautCPPosnerMDesaiJMorganJAGeorgeSZahriehDFletcherCDDemetriGDBertagnolliMMSurgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors200624232531Search in Google Scholar
Rubió-Casadevall J, Martinez-Trufero J, Garcia-Albeniz X, Calabuig S, Lopez-Pousa A, Del Muro JG, Fra J, Redondo A, Lainez N, Poveda A, et al. Role of surgery in patients with recurrent, metastatic, or unresectable locally advanced gastrointestinal stromal tumors sensitive to imatinib: A retrospective analysis of the Spanish Group for Research on Sarcoma (GEIS). Ann Surg Oncol. 2015;22:2948–57.Rubió-CasadevallJMartinez-TruferoJGarcia-AlbenizXCalabuigSLopez-PousaADel MuroJGFraJRedondoALainezNPovedaARole of surgery in patients with recurrent, metastatic, or unresectable locally advanced gastrointestinal stromal tumors sensitive to imatinib: A retrospective analysis of the Spanish Group for Research on Sarcoma (GEIS)201522294857Search in Google Scholar
Bauer S, Hartmann JT, de Wit M, Lang H, Grabellus F, Antoch G, Niebel W, Erhard J, Ebeling P, Zeth M, et al. Resection of residual disease in patients with metastatic gastrointestinal stromal tumors responding to treatment with imatinib. Int J Cancer. 2005;117:316–25.BauerSHartmannJTde WitMLangHGrabellusFAntochGNiebelWErhardJEbelingPZethMResection of residual disease in patients with metastatic gastrointestinal stromal tumors responding to treatment with imatinib200511731625Search in Google Scholar
Zaydfudim V, Okuno SH, Que FG, Nagorney DM, Donohue JH. Role of operative therapy in treatment of tastatic gastrointestinal stromal tumors. J Surg Res. 2012;177:248–54.ZaydfudimVOkunoSHQueFGNagorneyDMDonohueJHRole of operative therapy in treatment of tastatic gastrointestinal stromal tumors201217724854Search in Google Scholar
Bamboat ZM, DeMatteo RP. Metastasectomy for gastrointestinal stromal tumors. J Surg Oncol. 2014;109:23–7.BamboatZMDeMatteoRPMetastasectomy for gastrointestinal stromal tumors2014109237Search in Google Scholar
Yeh CN, Chen TW, Tseng JH, Liu YY, Wang SY, Tsai CY, Chiang KC, Hwang TL, Jan YY, Chen MF. Surgical management in metastatic gastrointestinal stromal tumor (GIST) patients after imatinib mesylate treatment. J Surg Oncol. 2010;102:599–603.YehCNChenTWTsengJHLiuYYWangSYTsaiCYChiangKCHwangTLJanYYChenMFSurgical management in metastatic gastrointestinal stromal tumor (GIST) patients after imatinib mesylate treatment2010102599603Search in Google Scholar
An HJ, Ryu MH, Ryoo BY, Sohn BS, Kim KH, Oh ST, Yu CS, Yook JH, Kim BS, Kang YK. The effects of surgical cytoreduction prior to imatinib therapy on the prognosis of patients with advanced GIST. Ann Surg Oncol. 2013, 20:4212–8.AnHJRyuMHRyooBYSohnBSKimKHOhSTYuCSYookJHKimBSKangYKThe effects of surgical cytoreduction prior to imatinib therapy on the prognosis of patients with advanced GIST20132042128Search in Google Scholar
Julio Sánchez-Meca, Juan Botella. Systematic reviews and metaanalyses: Tools for professional practice. Papeles del Psicólogo 2010, 31: 7–17.Sánchez-MecaJulioBotellaJuanSystematic reviews and metaanalyses: Tools for professional practice201031717Search in Google Scholar
Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J. Methodological index for non-randomized studies (MINORS): Development and validation of a new instrument. ANZ J Surg. 2003;73:712–6.SlimKNiniEForestierDKwiatkowskiFPanisYChipponiJMethodological index for non-randomized studies (MINORS): Development and validation of a new instrument2003737126Search in Google Scholar
Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 2010; 25: 603–5.StangACritical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses2010256035Search in Google Scholar
Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994;50:1088–101.BeggCBMazumdarMOperating characteristics of a rank correlation test for publication bias1994501088101Search in Google Scholar
Egger M, Davey SG, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ (Clin Res Ed) 1997;315:629–34.EggerMDaveySGSchneiderMMinderCBias in meta-analysis detected by a simple, graphical test199731562934Search in Google Scholar
Chang SC, Liao CH, Wang SY, Tsai CY, Chiang KC, Cheng CT, Yeh TS, Chen YY, Ma MC, Liu CT, et al. Feasibility and Timing of Cytoreduction Surgery in Advanced (Metastatic or Recurrent) Gastrointestinal Stromal Tumors During the Era of Imatinib. Medicine (Baltimore). 2015;94:e1014.ChangSCLiaoCHWangSYTsaiCYChiangKCChengCTYehTSChenYYMaMCLiuCTFeasibility and Timing of Cytoreduction Surgery in Advanced (Metastatic or Recurrent) Gastrointestinal Stromal Tumors During the Era of Imatinib201594e1014Search in Google Scholar
Sato S, Tsujinaka T, Masuzawa T, Yamamoto K, Takahashi T, Yamashita Y, Fujita J, Takagi M, Hirota S, Nishida T. Role of metastasectomy for recurrent/metastatic gastrointestinal stromal tumors based on an analysis of the Kinki GIST registry. Surg Today. 2017;47:58–64.SatoSTsujinakaTMasuzawaTYamamotoKTakahashiTYamashitaYFujitaJTakagiMHirotaSNishidaTRole of metastasectomy for recurrent/metastatic gastrointestinal stromal tumors based on an analysis of the Kinki GIST registry2017475864Search in Google Scholar
Shi YN, Li Y, Wang LP, Wang ZH, Liang XB, Liang H, Zhang L, Li B, Fan LQ, Zhao Q, et al. Gastrointestinal stromal tumor (GIST) with liver metastases: An 18-year experience from the GIST cooperation group in North China. Medicine (Baltimore). 2017;96:e8240.ShiYNLiYWangLPWangZHLiangXBLiangHZhangLLiBFanLQZhaoQGastrointestinal stromal tumor (GIST) with liver metastases: An 18-year experience from the GIST cooperation group in North China201796e8240Search in Google Scholar
Xiao B, Peng J, Tang J, Zhang R, Li C, Lin J, Ding P, Wan D, Pan Z, Wu X. Liver surgery prolongs the survival of patients with gastrointestinal stromal tumor liver metastasis: a retrospective study from a single center. Cancer Manag Res. 2018;10:6121–7.XiaoBPengJTangJZhangRLiCLinJDingPWanDPanZWuXLiver surgery prolongs the survival of patients with gastrointestinal stromal tumor liver metastasis: a retrospective study from a single center20181061217Search in Google Scholar
Xia L, Zhang MM, Ji L, Li X, Wu XT. Resection combined with imatinib therapy for liver metastases of gastrointestinal stromal tumors. Surg Today. 2010;40:936–42.XiaLZhangMMJiLLiXWuXTResection combined with imatinib therapy for liver metastases of gastrointestinal stromal tumors20104093642Search in Google Scholar
Xue A, Gao X, He Y, Shu P, Huang X, Sun J, Lu J, Hou Y, Fang Y, Shen K. Role of Surgery in the Management of Liver Metastases From Gastrointestinal Stromal Tumors. Front Oncol. 2022;12:903487.XueAGaoXHeYShuPHuangXSunJLuJHouYFangYShenKRole of Surgery in the Management of Liver Metastases From Gastrointestinal Stromal Tumors202212903487Search in Google Scholar
Du CY, Zhou Y, Song C, Wang YP, Jie ZG, He YL, Liang XB, Cao H, Yan ZS, Shi YQ. Is there a role for surgery in patients with recurrent or metastatic gastrointestinal stromal tumours responding toimatinib: A prospective randomised trial in China. Eur J Cancer 2014,50:1772–8.DuCYZhouYSongCWangYPJieZGHeYLLiangXBCaoHYanZSShiYQIs there a role for surgery in patients with recurrent or metastatic gastrointestinal stromal tumours responding toimatinib: A prospective randomised trial in China20145017728Search in Google Scholar
Gao X, Xue A, Fang Y, Shu P, Ling J, Qin J, Hou Y, Shen K, Sun Y, Qin X. Role of surgery in patients with focally progressive gastrointestinal stromal tumors resistant to imatinib. Sci Rep. 2016;6:22840.GaoXXueAFangYShuPLingJQinJHouYShenKSunYQinXRole of surgery in patients with focally progressive gastrointestinal stromal tumors resistant to imatinib2016622840Search in Google Scholar
Mussi C, Ronellenfitsch U, Jakob J, Tamborini E, Reichardt P, Casali PG, Fiore M, Hohenberger P, Gronchi A. Post-imatinib surgery in advanced/metastaticGIST: Is it worthwhile in all patients? Ann Oncol. 2010;21:403–8.MussiCRonellenfitschUJakobJTamboriniEReichardtPCasaliPGFioreMHohenbergerPGronchiAPost-imatinib surgery in advanced/metastaticGIST: Is it worthwhile in all patients?2010214038Search in Google Scholar
Debiec-Rychter M, Sciot R, Le Cesne A, Schlemmer M, Hohenberger P, van Oosterom AT, Blay JY, Leyvraz S, Stul M, Casali PG, et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 2006;42:1093.Debiec-RychterMSciotRLe CesneASchlemmerMHohenbergerPvan OosteromATBlayJYLeyvrazSStulMCasaliPGKIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours2006421093Search in Google Scholar
Heinrich MC, Owzar K, Corless CL, Hollis D, Borden EC, Fletcher CD, Ryan CW, von Mehren M, Blanke CD, Rankin C, et al. Correlation of kinase genotype and clinical outcome in the North American Intergroup phase III trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. J Clin Oncol. 2008;26:5360.HeinrichMCOwzarKCorlessCLHollisDBordenECFletcherCDRyanCWvon MehrenMBlankeCDRankinCCorrelation of kinase genotype and clinical outcome in the North American Intergroup phase III trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group2008265360Search in Google Scholar
Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H, McGreevey LS, Chen CJ, Van den Abbeele AD, Druker BJ, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol. 2003;21:4342.HeinrichMCCorlessCLDemetriGDBlankeCDvon MehrenMJoensuuHMcGreeveyLSChenCJVan den AbbeeleADDrukerBJKinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor2003214342Search in Google Scholar
Hasegawa J, Kanda T, Hirota S, Fukuda M, Nishitani A, Takahashi T, Kurosaki I, Tsutsui S, Hatakeyama K, Nishida T. Surgical interventions for focal progression of advanced gastrointestinal stromal tumors during imatinib therapy. Int J Clin Oncol. 2007;12:212–7.HasegawaJKandaTHirotaSFukudaMNishitaniATakahashiTKurosakiITsutsuiSHatakeyamaKNishidaTSurgical interventions for focal progression of advanced gastrointestinal stromal tumors during imatinib therapy2007122127Search in Google Scholar
Bauer S, Rutkowski P, Hohenberger P, Miceli R, Fumagalli E, Siedlecki JA, Nguyen BP, Kerst M, Fiore M, Nyckowski P, et al. Long-term follow-up of patients with GIST undergoing metastasectomy in the era of imatinib: Analysis of prognostic factors (EORTC-STBSG collaborative study). Eur J Surg Oncol. 2014;40:412–9..BauerSRutkowskiPHohenbergerPMiceliRFumagalliESiedleckiJANguyenBPKerstMFioreMNyckowskiPLong-term follow-up of patients with GIST undergoing metastasectomy in the era of imatinib: Analysis of prognostic factors (EORTC-STBSG collaborative study)2014404129Search in Google Scholar
Chen Q, Li C, Yang H, Zhao H, Wu J, Zhao J, Bi X, Li Z, Huang Z, Zhang Y, et al. Resection Combined with TKI Therapy for Resectable Liver Metastases of Gastrointestinal Stromal Tumours: Results from Three National Centres in China. J Gastrointest Surg. 2020;24:1330–41.ChenQLiCYangHZhaoHWuJZhaoJBiXLiZHuangZZhangYResection Combined with TKI Therapy for Resectable Liver Metastases of Gastrointestinal Stromal Tumours: Results from Three National Centres in China202024133041Search in Google Scholar
Turley RS, Peng PD, Reddy SK, Barbas AS, Geller DA, Marsh JW, Tsung A, Pawlik TM, Clary BM. Hepatic resection for metastatic gastrointestinal stromal tumors in the tyrosine kinase inhibitor era. Cancer. 2012;118:3571–8.TurleyRSPengPDReddySKBarbasASGellerDAMarshJWTsungAPawlikTMClaryBMHepatic resection for metastatic gastrointestinal stromal tumors in the tyrosine kinase inhibitor era201211835718Search in Google Scholar
Kraft A, Croitoru A, Gheorghe C, Lupescu I, Grasu M, Tomescu D, Droc G, Herlea V, Barcu A, Popescu I, et al. Liver Resection for Metastases from Gastrointestinal Stromal Tumors: Does it Improve Long-Term Survival? Chirurgia (Bucur). 2021;116:438–50.KraftACroitoruAGheorgheCLupescuIGrasuMTomescuDDrocGHerleaVBarcuAPopescuILiver Resection for Metastases from Gastrointestinal Stromal Tumors: Does it Improve Long-Term Survival?202111643850Search in Google Scholar
Seesing MF, Tielen R, van Hillegersberg R, van Coevorden F, de Jong KP, Nagtegaal ID, Verhoef C, de Wilt JH; Dutch Liver Surgery Working Group. Resection of liver metastases in patients with gastrointestinal stromal tumors in the imatinib era: A nationwide retrospective study. Eur J Surg Oncol. 2016;42:1407–13.SeesingMFTielenRvan HillegersbergRvan CoevordenFde JongKPNagtegaalIDVerhoefCde WiltJHDutch Liver Surgery Working GroupResection of liver metastases in patients with gastrointestinal stromal tumors in the imatinib era: A nationwide retrospective study201642140713Search in Google Scholar